

Science; a Grant-in-Aid from the Research Committee of CNS Degenerative Diseases and Comprehensive Research on Disability Health and Welfare, Ministry of Health, Labor and Welfare, Japan; a Grant-in-Aid from the Uehara Memorial Foundation; a Grant-in-Aid from the Tsubaki Memorial Foundation; and a Grant-in-Aid for JSPS Fellows from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors declare no conflicts of interest.

REFERENCES

1. Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. *Annu Rev Neurosci* 2010; **33**: 409–440.
2. Clowney EJ, LeGros MA, Mosley CP *et al.* Nuclear aggregation of olfactory receptor genes governs their monogenic expression. *Cell* 2012; **151**: 724–737.
3. Lafarga M, Casafont I, Bengoechea R, Tapia O, Berciano MT. Cajal's contribution to the knowledge of the neuronal cell nucleus. *Chromosoma*. Springer 2009; **118**: 437–443.
4. Kwong LK, Neumann M, Sampathu DM, Lee VMY, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. *Acta Neuropathol* 2007; **114** (1): 63–70.
5. Geser F, Lee VMY, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. *Neuropathology* 2010; **30**: 103–112.
6. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* 2010; **19** (R1): R46–R64.
7. Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. *Hum Mutat* 2013; **34**: 812–826.
8. Yokoseki A, Shiga A, Tan C-F *et al.* TDP-43 mutation in familial amyotrophic lateral sclerosis. *Ann Neurol* 2008; **63**: 538–542.
9. Wang IF, Reddy NM, Shen CKJ. Higher order arrangement of the eukaryotic nuclear bodies. *Proc Natl Acad Sci U S A* 2002; **99**: 13583–13588.
10. Casafont I, Bengoechea R, Tapia O, Berciano MT, Lafarga M. TDP-43 localizes in mRNA transcription and processing sites in mammalian neurons. *J Struct Biol* 2009; **167**: 235–241.
11. Zhang ZC, Chook YM. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). *Proc Natl Acad Sci U S A* 2012; **109**: 12017–12021.
12. Tan C-F, Eguchi H, Tagawa A *et al.* TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. *Acta Neuropathol* 2007; **113**: 535–542.
13. Mori F, Tanji K, Zhang H-X *et al.* Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. *Acta Neuropathol* 2008; **116**: 193–203.
14. Lee EB, Lee VMY, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. *Nat Rev Neurosci* 2012; **13** (1): 38–50.
15. Onodera O, Sugai A, Konno T, Tada M, Koyama A, Nishizawa M. What is the key player in TDP-43 pathology in ALS: disappearance from the nucleus or inclusion formation in the cytoplasm? *Neurol. Clin Neurosci* 2013; **1** (1): 11–17.
16. Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. *J Mol Neurosci* 2011; **45**: 486–499.
17. Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. *Trends Biochem Sci* 2012; **37**: 237–247.
18. Polymenidou M, Lagier-Tourenne C, Hutt KR *et al.* Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* 2011; **14**: 459–468.
19. Tollervey JR, Curk T, Rogelj B *et al.* Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* 2011; **14**: 452–458.
20. Jiang Y-M, Yamamoto M, Kobayashi Y *et al.* Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. *Ann Neurol* 2005; **57**: 236–251.
21. Rabin SJ, Kim JMH, Baughn M *et al.* Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology. *Hum Mol Genet* 2010; **19**: 313–328.
22. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. Misregulated RNA processing in amyotrophic lateral sclerosis. *Brain Res* 2012; **1462**: 3–15.
23. Tollervey JR, Wang Z, Hortobágyi T *et al.* Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. *Genome Res* 2011; **21**: 1572–1582.
24. Shiga A, Ishihara T, Miyashita A *et al.* Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. *PLoS ONE* 2012; **7** (8): e43120.

25. Lagier-Tourenne C, Polymenidou M, Hutt KR *et al*. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. *Nat Neurosci* 2012; **15**: 1488–1497.
26. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. *Proc Natl Acad Sci U S A* 2012; **109**: 3347–3352.
27. Mao YS, Zhang B, Spector DL. Biogenesis and function of nuclear bodies. *Trends Genet* 2011; **27**: 295–306.
28. Caudron-Herger M, Rippe K. Nuclear architecture by RNA. *Curr Opin Genet Dev* 2012; **22**: 179–187.
29. Dundr M. Nuclear bodies: multifunctional companions of the genome. *Curr Opin Cell Biol* 2012; **24**: 415–422.
30. Nizami Z, Deryusheva S, Gall JG. The Cajal body and histone locus body. *Cold Spring Harb Perspect Biol* 2010; **2** (7): a000653.
31. Morris GE. The Cajal body. *Biochim Biophys Acta* 2008; **1783**: 2108–2115.
32. Strzelecka M, Trowitzsch S, Weber G, LUhrmann R, Oates AC, Neugebauer KM. Coilin-dependent snRNP assembly is essential for zebrafish embryogenesis. *Nat Struct Mol Biol* 2010; **17**: 403–409.
33. Machyna M, Heyn P, Neugebauer KM. Cajal bodies: where form meets function. *Wiley Interdiscip Rev RNA* 2013; **4** (1): 17–34.
34. Ishihara T, Ariizumi Y, Shiga A *et al*. Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. *Hum Mol Genet* 2013. doi: 10.1093/hmg/ddt262
35. Shan X, Chiang P-M, Price DL, Wong PC. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. *Proc Natl Acad Sci U S A* 2010; **107**: 16325–16330.
36. Lefebvre S, Burlet P, Liu Q *et al*. Correlation between severity and SMN protein level in spinal muscular atrophy. *Nat Genet* 1997; **16**: 265–269.
37. Tsuiji H, Iguchi Y, Furuya A *et al*. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. *EMBO Mol Med* 2013; **5**: 221–234.
38. Avendaño-Vázquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. *Genes Dev* 2012; **26**: 1679–1684.
39. Pena E, Berciano MT, Fernandez R, Ojeda JL, Lafarga M. Neuronal body size correlates with the number of nucleoli and Cajal bodies, and with the organization of the splicing machinery in rat trigeminal ganglion neurons. *J Comp Neurol* 2001; **430**: 250–263.
40. Berciano MT, Novell M, Villagra NT *et al*. Cajal body number and nucleolar size correlate with the cell body mass in human sensory ganglia neurons. *J Struct Biol* 2007; **158**: 410–420.
41. Oyanagi K, Ikuta F, Horikawa Y. Evidence for sequential degeneration of the neurons in the intermediate zone of the spinal cord in amyotrophic lateral sclerosis: a topographic and quantitative investigation. *Acta Neuropathol* 1989; **77**: 343–349.
42. Frey MR, Matera AG. RNA-mediated interaction of Cajal bodies and U2 snRNA genes. *J Cell Biol* 2001; **154**: 499–509.
43. Jordan BA, Fernholz BD, Khatri L, Ziff EB. Activity-dependent AIDA-1 nuclear signaling regulates nucleolar numbers and protein synthesis in neurons. *Nat Neurosci* 2007; **10**: 427–435.
44. Dundr M, Misteli T. Biogenesis of nuclear bodies. *Cold Spring Harb Perspect Biol* 2010; **2** (12): a000711.
45. Shevtsov SP, Dundr M. Nucleation of nuclear bodies by RNA. *Nat Cell Biol* 2011; **13**: 167–173.
46. Bose JK, Wang IF, Hung L, Tarn W-Y, Shen CKJ. TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. *J Biol Chem* 2008; **283**: 28852–28859.
47. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? *Nat Rev Neurosci* 2009; **10**: 597–609.
48. Piao Y, Hashimoto T, Takahama S *et al*. Survival motor neuron (SMN) protein in the spinal anterior horn cells of patients with sporadic amyotrophic lateral sclerosis. *Brain Res* 2011; **4** (1372): 152–159.
49. Yamazaki T, Chen S, Yu Y *et al*. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. *Cell Rep* 2012; **2**: 799–806.
50. Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. *J Proteome Res* 2010; **9**: 1104–1120.
51. Dundr M, Hebert MD, Karpova TS *et al*. In vivo kinetics of Cajal body components. *J Cell Biol* 2004; **164**: 831–842.
52. Coady TH, Lorson CL. SMN in spinal muscular atrophy and snRNP biogenesis. *Wiley Interdiscip Rev RNA* 2011; **2**: 546–564.
53. Neuenkirchen N, Chari A, Fischer U. Deciphering the assembly pathway of Sm-class U snRNPs. *FEBS Lett* 2008; **582**: 1997–2003.
54. Zhang Z, Lotti F, Dittmar K *et al*. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. *Cell* 2008; **133**: 585–600.
55. Gabanella F, Butchbach MER, Saieva L, Carissimi C, Burghes AHM, Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular

- atrophy severity and preferentially affect a subset of spliceosomal snRNPs. *PLoS ONE* 2007; **2** (9): e921.
56. Turunen JJ, Niemela EH, Verma B, Frilander MJ. The significant other: splicing by the minor spliceosome. *Wiley Interdiscip Rev RNA* 2013; **4**: 61–76.
 57. Lander ES, Linton LM, Birren B *et al*. Initial sequencing and analysis of the human genome. *Nature* 2001; **409** (6822): 860–921.
 58. Patel AA, McCarthy M, Steitz JA. The splicing of U12-type introns can be a rate-limiting step in gene expression. *EMBO J* 2002; **21**: 3804–3815.
 59. Padgett RA. New connections between splicing and human disease. *Trends Genet* 2012; **28**: 147–154.
 60. Pierce MJ, Morse RP. The neurologic findings in Taybi-Linder syndrome (MOPD I/III): case report and review of the literature. *Am J Med Genet* 2012; **158A**: 606–610.
 61. Edery P, Marcaillou C, Sahbatou M *et al*. Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. *Science* 2011; **332** (6026): 240–243.
 62. He H, Liyanarachchi S, Akagi K *et al*. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. *Science* 2011; **332** (6026): 238–240.
 63. Abdel-Salam GMH, Abdel-Hamid MS, Issa M, Magdy A, El-Kotoury A, Amr K. Expanding the phenotypic and mutational spectrum in microcephalic osteodysplastic primordial dwarfism type I. *Am J Med Genet* 2012; **158A**: 1455–1461.
 64. Jia Y, Mu JC, Ackerman SL. Mutation of a U2 snRNA gene causes global disruption of alternative splicing and neurodegeneration. *Cell* 2012; **148** (1–2): 296–308.
 65. O'Reilly D, Dienstbier M, Cowley SA *et al*. Differentially expressed, variant U1 snRNAs regulate gene expression in human cells. *Genome Res* 2013; **23**: 281–291.
 66. Lotti F, Imlach WL, Saieva L *et al*. An SMN-dependent U12 splicing event essential for motor circuit function. *Cell* 2012; **151**: 440–454.
 67. Roselli F, Caroni P. A circuit mechanism for neurodegeneration. *Cell* 2012; **151**: 250–252.
 68. Imlach WL, Beck ES, Choi BJ, Lotti F, Pellizzoni L, McCabe BD. SMN is required for sensory-motor circuit function in *Drosophila*. *Cell* 2012; **151**: 427–439.
 69. Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. *J Clin Invest* 2009; **119**: 1825–1836.
 70. Dechat T, Pflieger K, Sengupta K *et al*. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. *Genes Dev* 2008; **22**: 832–853.
 71. Zuela N, Bar DZ, Gruenbaum Y. Lamins in development, tissue maintenance and stress. *EMBO Rep* 2012; **13**: 1070–1078.
 72. Jung H-J, Lee JM, Yang SH, Young SG, Fong LG. Nuclear lamins in the brain – new insights into function and regulation. *Mol Neurobiol* 2013; **47** (1): 290–301.

異常タンパク伝播仮説に基づく神経疾患の画期的治療法の開発
平成 25 年度 班会議プログラム

■日時:平成 26 年 1 月 23 日(木)10:30~17:10

■会場:公益財団法人東京都医学総合研究所 S 棟 2 階 会議室 2B・2C

(敬省略)

10:00~	受付	
10:30~10:35	開会挨拶 (研究代表者 長谷川 成人)	
	《TDP-43、FUS、C9orf72 第1部》	座長 野中 隆
10:35~10:55	1. 患者脳に蓄積した TDP-43 のプリオン様性質 演者:野中 隆 (公益財団法人東京都医学総合研究所 認知症プロジェクト)	
10:55~11:15	2. ALS および FTLD-TDP 患者脳中に蓄積した TDP-43 のプロテアーゼ耐性断片の解析 演者:亀谷 富由樹 (公益財団法人東京都医学総合研究所 認知症プロジェクト)	
11:15~11:35	3. TDP-43 の凝集に関わる配列 久永 眞市 (首都大学東京 大学院理工学研究科 生命科学専攻 神経分子機能研究室) 演者:下中 翔太郎 (首都大学東京 大学院理工学研究科 生命科学専攻 神経分子機能研究室、公益財団法人東京都医学総合研究所 認知症プロジェクト)	
11:35~11:55	4. 筋萎縮性側索硬化症とGuillain-Barré症候群の鑑別診断 演者:細川 雅人 (公益財団法人東京都医学総合研究所 認知症プロジェクト)	
11:55~12:15	5. TDP-43 量は自己mRNAのpolyA選択、スプライシング、核貯留の協働により制御される 小野寺 理 (新潟大学脳研究所分子神経疾患資源解析学分野) 演者:須貝 章弘 (新潟大学脳研究所神経内科)	
12:15~13:30	昼 食	
	《TDP-43、FUS、C9orf72 第2部》	座長 村山 繁雄
13:30~13:50	6. 運動ニューロン疾患で見られるELP3抗体陽性封入体 演者:藤田 行雄 (群馬大学大学院脳神経内科学)	
13:50~14:10	7. 急速に呼吸筋麻痺が進行し好塩基封入体を認めた ALS 演者:吉田 眞理 (愛知医科大学加齢医学研究所)	
14:10~14:30	8. 本邦における FTLD-FUS の特徴 演者:秋山 治彦 (公益財団法人東京都医学総合研究所 認知症プロジェクト)	
14:30~14:50	9. C9orf72 変異を有する日本人 ALS の一剖検例 高橋 均 (新潟大学脳研究所病理学分野) 演者:今野 卓哉 (新潟大学脳研究所神経内科学分野)	
14:50~15:05	休 憩	

≪ α syn、Tau 第1部 ≫ 座長 高橋 均	
15:05~15:25	10. Parkinson 病および Lewy 小体型認知症における延髄のリン酸化 α -synuclein 陽性構造の検討 演者: 新井 哲明 (筑波大学医学医療系臨床医学域精神医学)
15:25~15:45	11. レビー小体関連 α シヌクレイオパチー (Lewy body- related α -synucleinopathy: LBAS) の脊髄内伝播に関する研究 村山 繁雄 (東京都健康長寿医療センター高齢者ブレインバンク) 演者: 隅蔵 大幸 (東京都健康長寿医療センター高齢者ブレインバンク)
15:45~16:05	12. 発症前進行性核上性麻痺 (preclinical progressive supranuclear palsy) の提唱 村山 繁雄 (東京都健康長寿医療センター高齢者ブレインバンク) 演者: 野上 茜 (東京都健康長寿医療センター高齢者ブレインバンク)
16:05~16:25	13. 神経疾患脳に蓄積するタウの生化学解析 演者: 長谷川 成人 (公益財団法人東京都医学総合研究所 認知症プロジェクト)
≪ α syn、Tau 第2部 ≫ 座長 長谷川 成人	
16:25~16:45	14. α シヌクレインのプリオン様伝播 長谷川 成人 (公益財団法人東京都医学総合研究所 認知症プロジェクト) 演者: 鈴掛 雅美 (公益財団法人東京都医学総合研究所 認知症プロジェクト)
16:45~17:05	15. 霊長類 ALS 蛋白伝播モデル作製の試み 演者: 横田 隆徳 (東京医科歯科大学大学院 脳神経病態学(神経内科))
17:05~	閉会挨拶 (研究代表者 長谷川 成人)

